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Abstract
Background: To determine the prevalence of smoking and analyze associated factors in a cohort of patients
diagnosed with tuberculosis (TB) in Spain between 2006 and 2013.
Methods: Multicenter, cross-sectional, descriptive, observational study using a national database of TB patients,
using logistic regression to calculate odds ratios (OR) and confidence intervals (CI).
Results: We analyzed 5,846 cases (62 % men, mean age 39 years, 33 % foreigners). 23.4 % were alcohol abuser, 1.3 %
were injected drug users (IDU), 4.6 % were co-infected with HIV, and 7.5 % had a history of TB treatment. 6.6 % and 0.
8 % showed resistance to one and multiple drugs, respectively. The predominant clinical presentation was pulmonary
(71 %) with a cavitary radiological pattern in 32.8 % of cases. 82 % of cases were confirmed microbiologically, and 54 %
were smear-positive microscopy.
2,300 (39.3 %) patients were smokers. The following factors were associated with smoking: male sex (OR = 2.26;CI:1.97;2.
60), Spanish origin (OR = 2.79;CI:2.40–3.24), alcoholism (OR = 2.85;CI:2.46;3.31), IDU (OR = 2.78;CI:1.48;5.52), homelessness
(OR = 1.99;CI:1.14–3.57), pulmonary TB (OR = 1.61;CI:1.16;2.24), cavitary radiological pattern (OR = 1.99;CI:1.43;2.79) and a
smear-positive microscopy at the time of diagnosis (OR = 1.39;CI:1.14;1.17).
Conclusions: The prevalence of smoking among TB patients is high. Smokers with TB have a distinct sociodemographic,
clinical, radiological and microbiological profile to non-smokers.
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Background
Smoking and tuberculosis (TB) are two of the biggest
public health problems worldwide [1]. Smoking is one of
the leading preventable causes of premature death, pro-
ducing 6 million deaths a year. At present, about 33 % of
the world population smokes, mainly in countries with a
high prevalence of TB. In turn, TB causes 9.6 million in-
cident cases and 1.5 million deaths in 2014 [2, 3].
While, the relationship between smoking and TB has
been recognized for almost a century, the impact of
smoking on TB has only been demonstrated in last
decade [4–7]: both active and passive exposure to smoke
are independent risk factors for TB infection [8, 9], the
progression of TB infection to disease [10, 11], greater
disease severity, and increased risk of post-treatment
relapse and mortality [12–14].
A recent study based on mathematical modelling esti-
mated that, between 2010 and 2050, smoking could raise
the number of TB cases worldwide by 18 million, and
substantially increase secondary mortality if current
trends in tobacco consumption are maintained [15].
The World Health Organization and the International
Union Against Tuberculosis and Lung Disease issued
regulations in 2007 to control these two clearly re-
lated epidemics [1].
Smoking prevalence among TB patients could be
higher than the objectified general population in many
countries; in China a case-control study shows
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prevalence of 54.6 % [16], in South Africa found that
56 % of people with active TB were smokers [17], a study
in rural India found that 81.5 % of TB cases had previ-
ously smoked at some time in their life [18] and in
Georgia the prevalence of current smokers among the
diagnoses of TB represents 45.9 % [19]. Currently, there
are no reliable data on the prevalence of smoking among
TB patients in Spain, with the exception of one study
carried out in Catalonia between 1996 and 2002, which
reported a smoking prevalence of 34.9 % [12].
The aim of our study was to determine the prevalence
of smoking among patients diagnosed with TB in Spain
between 2006 and 2013, and to identify factors asso-
ciated with smoking in this population. The ultimate
goal is to design assistance and support strategies for
smoking cessation to improve clinical outcomes, re-
duce TB transmissibility, and improve prognosis and
survival.
Methods
We performed a multicenter, cross-sectional, descriptive,
analytical and observational study.
We included patients diagnosed with TB between 1
January 2006 and 31 December 2013 within the catch-
ment area of the Integrated TB Research Program (PII
TB) Working Group of the Spanish Society of Pneumol-
ogy and Thoracic Surgery (SEPAR) in 60 centers in
Spanish Autonomous Communities.
We included patients aged >18 years with a diagnosis
of TB, as determined by: 1) positive smear, or negative
smear with positive culture for Mycobacterium tubercu-
losis, or extra-pulmonary TB as demonstrated by granu-
lomas tubercular on histology; 2) patients suspected TB
(clinical, radiological, epidemiological and/or laboratory
results) with a good response to TB treatment without
other diagnosis.
Patients were considered to be smokers if they re-
ported having smoked ≥1 cigarettes per day continu-
ously during the year preceding the diagnosis of TB and
no smoker the person who has smoked less than 100
cigarettes in his life [20].
The information is collected by clinical researcher
from the interview and review of the history in three
visits: at the time of diagnosis, the second month and
the end of treatment. For all cases, we collected socio-
demographic data, living status, origin (native or immi-
grant), place of diagnosis, alcohol consumption (men
consuming over 280 g alcohol per week, an women over
168 gr, were considered alcoholics), use of intravenous
heroin or/and cocaine drugs (IDU), delayed diagnosis
(>50 days), TB localization, radiology, microbiology re-
sults and sensitivity study, history of TB, HIV infection,
clinical progression, drug treatment, and treatment out-
come (correct: cured, treatment completed; incorrect:
therapeutic failure, moved away/transferred, lost to
follow-up and death).
The information obtained from each patient was
stored in an electronic data collection notebook (DCN)
implemented in a software application available to
each study investigator via a personal identifier and
password.
The study was conducted according to the require-
ments of the Declaration of Helsinki and Spanish Data
Protection Law 15/1999. All patients gave their informed
consent to participate in this study, which was approved
by the Clinical Research Ethics Committee of Vall
d'Hebron University Hospital Foundation - Research
Institute.
Statistical analysis
We performed a descriptive study of the prevalence of
smoking among participants, and the frequency distribu-
tion of other variables. We performed bivariate analysis
of factors potentially associated with smoking (yes/no)
by comparing proportions between groups using the χ2
test. Results with p < 0.05 were considered statistically
significant. For the multivariable analysis, we fit logistic
regression models using the backward stepwise selection
method to include variables that were relevant to the
study, as well as those with p < 0.001 in the bivariate
analysis, and to compute Odds Ratios (OR) and 95 %
Confidence Intervals (CI). We used the Hosmer-
Lemeshow test to evaluate the goodness of fit of each
model. All analysis was performed using IBM SPSS
Statistic19.
Results
We included 5,846 TB patients; with a mean age of
39 years (range 18–100 years), 3,626 (62 %) men, and
1,941 foreigners (33 %). 23.4 % were pathological alcohol
drinkers, and 1.3 % were IDU. 4.6 % of cases were coin-
fected with HIV, 438 (7.5 %) had a history of TB treat-
ment, and 49.5 % were diagnosed by hospital emergency
services. 6.6 % of cases were found to be resistant to any
drug, and 0.8 % to multiple drugs. The predominant
clinical presentation was pulmonary tuberculosis (4,149
cases, 71 %), with a cavitary radiological pattern in
32.8 % of cases. 82 % of cases were confirmed microbio-
logically, of which 54 % were smear-positive.
A total of 2,300 (39.3 %) patients were smokers, and
this proportion remained stable during the course of the
study Fig. 1.
The bivariate analysis to detect factors associated with
smoking (Table 1) indicated a higher prevalence of
smoking among men, Spanish nationals, and individuals
who live alone or in confinement, or who are homeless,
regardless of age or employment status. Smoking was
also associated with other harmful habits, such as
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alcoholism and the use of injected drugs. Smoking was
more frequent in cases with coexisting HIV infection,
and those with a history of TB treatment. The preva-
lence of delayed diagnosis was significantly higher in
smokers than in non-smokers. Pulmonary forms of TB,
radiological cavitation, and positive smear-test results
were more common in smokers, as was therapeutic non-
compliance, and the need for directly observed treatment
(DOT) administration and poorer treatment outcome. In
contrast, we observed no differences between smokers
and non-smokers in terms of single or multi-drug resist-
ance, prescribed treatment, or clinical or radiological pro-
gression (Table 1).
The multivariate analysis (Table 2) showed that the
following factors were associated with smoking at the
time of diagnosis in this cohort of TB patients: male
gender (OR = 2.26,CI 1.97–2.60), being native Spanish
(OR = 2.79,CI 2.40–3.24), alcohol consumption (OR =
2.85,CI 2.46–3.31), IDU (OR = 2.78,CI 1.48–5.52), pov-
erty (OR = 1.99,CI 1.14–3.57), pulmonary forms of TB
(OR = 1.61,CI 1.16–2.24), cavitary radiological patterns
(OR = 1.99,CI 1.43–2.79) and positive smear-test results
(OR = 1.39, CI 1.14–1.71).
Discussion
We observed a high prevalence of smoking among indi-
viduals diagnosed with TB in Spain between 2006 and
2013. Smoking was associated with male gender, being
native Spanish, the consumption of other drugs, a pre-
carious social position, more severe and more developed
lung disease, and poorer treatment outcome than in
non-smoking TB patients.
In this study, we found that 39.3 % of TB patients were
regular smokers at the time of diagnosis, a much higher
figure than that reported for the general population in
Spain, 23.95 %, according to data from the National
Health Survey 2011–2013 and it remained well above
this value, and with little annual variation (Fig. 1); this
level was similar to that published for Catalonia in 2002
(34.9 %) [12]. However, during the period of this study,
we observed a steady decline in smoking prevalence in
Spain, 26.44 % in 2006 to 23.95 % in 2013 [21], as a re-
sult of legislative changes and prevention programs [22].
Thus, the TB patients smokers may be resistant to gen-
eral anti-smoking measures, possibly for social reasons
or because of differences in its level of addiction to nico-
tine. This hinders smoking cessation in this group, and
highlights the need for a different set of cessation strat-
egies to those used in the general population.
In our sample, we found that men smoke significantly
more than women; 62 % of men with TB were smokers,
compared to 27.87 % of males in the general population
during the same period. In comparison, the prevalence
of smoking among female TB patients (25.3 %) was only
5 percentage points higher than in the general popula-
tion (20.2 %). Worldwide, TB is known to be more com-
mon in men than in women. A study conducted in 22
countries with a high burden of TB found that smoking
was a predictor of increased reporting of TB in males
[23], suggesting that the differences in disease rates be-
tween sexes could be due to the higher prevalence of
smoking in men, a pattern that persists in virtually all
ethnic groups and countries [2].
While a third of the cases included in this study were
foreigners, the prevalence of smoking was much lower
in this group (27.5 %) than in native Spanish patients
(45.2 %). Previous studies carried out in Spain show that
the intensity of drug and alcohol consumption is lower
in the immigrant population than in natives. This pattern
has been attributed to cultural differences and economic
difficulties that reduce consumption, and is maintained in
immigrants with TB [24].
Smoking was also associated with situations of social
precariousness, and its prevalence was significantly
higher among individuals who live alone, in poverty, or
in confinement, regardless of their age or employment
status. Smoking was also associated with pathological
alcohol consumption (65.9 %) and injected drug use
(82.1 %). These risk factors are classically associated with
TB in people at risk of social marginalization, as previ-
ously described in our setting [12, 24, 25]. The propor-
tion of HIV co-infection was low in this sample (4.6 %),
and HIV was associated with tobacco use in the bivariate
but not multivariate analysis, possibly because of the low
number of co-infected cases. The clinical presentation of
TB in smokers was mainly pulmonary and disseminated,
Fig. 1 Trend in the prevalence of smoking in the general population
and among smokers with tuberculosis 2006–2013
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Table 1 Characteristics of 5,846 tuberculosis patients. Factors related to smoking at the time of tuberculosis diagnosis at
bivariate level
Total Non-smoker Smoker Bivariate analysis
N 5846 N 3546 61 % N 2300 39 % OR (95 % CI) P-value
Sex
Women 2082 1556 74,7 526 25,3 Ref
Men 3626 1911 52,7 1715 47,3 2.65(2.36;2.99) <0.001
Unknown 138 79 57,2 59 42,8 2.21(1.55;3.14) <0,001
Age
Unknown 138 118 85,5 20 15,5 Ref
18–30 years 1627 1077 66,2 550 33,8 2.99(1.88;5.01) <0,001
31–50 years 2405 1212 50,4 1193 49,6 5.77(3.65;9.61) <0,001
> 50 years 1676 1139 68 537 32 2.76(1.74;4.62) <0,001
Origin
Immigrant 1941 1408 72,5 533 27,5 Ref
Native 3905 2138 54,8 1767 45,2 2,18(1,94;2.46) <0,001
Cohabitation status
Group 651 431 66,2 220 33,8 Ref
Alone 554 276 49,8 278 50,2 1,97(1,56;2,49) <0,001
Homeless 100 25 25 75 75 5,84(3,65;9,63) <0,001
Confinement 80 38 47,5 42 52,5 2,16(1,35;3,47) 0,001
With Family 4293 2683 62,5 1610 37,5 1,18(0,99;1,40) 0,067
Unknown 168 93 55,4 75 44,6 1,58(1,12;2,23) 0,01
Employment status
Retired 978 792 81 186 19 Ref
Active 3026 1794 59,3 1232 40,7 2,92(2.46;3,95) <0.001
Unemployed 1481 730 49,3 751 50,7 4,38(3,63;5,30) <0.001
Incapacity 110 59 53,6 51 46,4 3,68(2,44;5,53) <0.001
Unknown 251 171 68,1 80 31,9 1,99(1,46;2,71) <0.001
Alcohol
No 4475 3079 68,8 1396 31,2 Ref
Yes 1371 467 34,1 904 65,9 4,27(3.76;4,86) <0,001
IDU
No 5768 3532 61,2 2236 38,8 Ref
Yes 78 14 17,9 64 82,1 7,15(4.12;13,4) <0,001
HIV
No 4547 2783 61,2 1764 38,8 1,10(0,96;1,27) 0,15
Yes 269 108 40,1 161 59,9 2,60(1,97;3,92) 0,001
Unknown 1030 655 63,5 375 36.4 Ref
Diagnosis
Specialits service 898 602 67 296 33 Ref
Hospital Emergency Room 2916 1691 58 1225 42 1,47(1,26;1,73) <0,001
Primere care 1106 660 59,7 446 40,3 1,37(1,14;1,65) 0,001
Other 754 494 65,5 260 34,5 1,07(0,87;1,31) 0,515
Unknown 172 99 57,6 73 42,4 1,5(1,07;2,09) 0,018
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Table 1 Characteristics of 5,846 tuberculosis patients. Factors related to smoking at the time of tuberculosis diagnosis at
bivariate level (Continued)
Prior Treatment
No 5287 3245 61,4 2042 38,6 Ref
Yes 438 224 51,1 214 48,9 1,52(1,25;1,85) <0,001
Localization
Extra-pulmonary 611 497 81,3 114 18,7 Ref
Pulmonary 4149 2299 55,4 1850 44,6 3,50(2.84;4.35) <0,001
Disseminated 301 198 65,8 103 34,2 2,27(1,66;3,10) <0,001
Unknown 785 552 70,3 233 29,7 1,84(1,43;2,38) <0,001
Radiology
Normal 610 480 78,7 130 21,3 Ref
Abnormal cavitary 1922 889 46,3 1033 53,7 4,28(3.47;5,32) <0,001
Abnormal non cavitary 3114 2042 65,6 1072 33,4 1,94(1,58;2,39) <0,001
Unknown 200 135 67,5 65 32,5 1,78(1,24;2,53) 0,002
Microbiology
Culture (−) 1055 779 73,8 276 26,2 Ref
Microscopy smear (+) 3144 1636 52 1508 48 2,60(2,23;3,04) <0,001
Microscopy smear (+), culture (−) 1647 1131 68,7 516 31,3 1,29(1,08;1,53) 0,004
Single-drug resistance
No 5458 3311 60,7 2147 39,3 Ref
Yes 388 235 60,6 153 39,4 1,00(0,81;1,24) 0,968
Multi-drug resistance
No 5797 3517 60,7 2280 39,3 Ref
Yes 49 29 59,2 20 40,8 1,07(0,59;1,88) 0,827
Delayed diagnosis
Unknown 343 226 65,9 117 34,1 Ref
< 50 days 2777 1680 60,5 1097 39,5 1,26(1,00;1,60) 0,052
> 50 days 2726 1640 60,2 1086 39,8 1,28(1,01;1,62) 0,04
Treatment indicated
Unknown 197 132 67 65 33 Ref
3 drugs 2566 1521 59,3 1045 40,7 1,39(1,03;1,91) 0,032
4 drugs 2819 1732 61,4 1087 38,6 1,27(0,94;1,74) 0,119
Others 264 161 61 103 39 1,30(0,88;1,92) 0,186
Need for DOT
Unknown 597 373 62,5 224 37,5 Ref
No 4629 2834 61,2 1795 38,8 1,05(0,89;1,26) 0,555
Yes 620 339 54,7 281 45,3 1,38(1,10;1,74) 0,006
Clinical progression
Unknown 569 354 62,2 215 37,8 Ref
Improved 4860 2936 60,4 1924 39,6 1,08(0,90;1,19) 0,406
Stable 368 226 61,4 142 38,6 1,03(0,79;1,35) 0,805
Progressed 49 30 61,2 19 38,8 1,05(0,56;1,89) 0,884
Radiological progression
Stable 981 626 63,8 355 36,2 Ref
Improved 3750 2238 59,7 1512 40,3 1,19(1,03;1,38) 0,018
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while isolated extra-pulmonary TB was rare in smokers.
Radiologically, we also observed more extensive lesions
in these patients, with more frequent cavitation and
positive smear results at the time of diagnosis. These
findings are similar to those reported by other authors,
mentioned above, and reflect generally more serious and
advanced disease [12, 13]. Several studies in animal
models and humans have shown that exposure to tobacco
smoke causes immunological changes, acting on alveolar
macrophages by decreasing the production of TNF-α,
IFN-γ, and mucociliary clearance, promoting disease pro-
gression [26–28], delaying sputum conversion and thereby
extending the period of transmissibility [29]. In this sense,
and in contrast to other studies [12], the observed delay in
diagnosis was also higher in smokers, possibly because
cough is a common symptom in these patients, and it
may be difficult to perceive changes that alert the subject
and motivate them to seek medical advice.
We did not find any significant differences between
smokers and non-smokers in the presence of single or
multi-drug resistance, or in the treatment initially indi-
cated, although directly observed therapy was indicated
more frequently in smokers than in non-smokers. Poorer
treatment outcome was also more common among
smokers. Therefore, smokers require closer monitoring
and greater resources to ensure therapeutic compliance
and the ultimate success of treatment, leading to in-
creased healthcare spending. Other studies have also
found a greater need for hospitalization, longer stays
[12], and increased risk of relapse following treatment. A
study in Taiwan found that people who smoke more
than 10 cigarettes per day have twice the risk of relapse
of non-smokers after proper treatment [14]. In our
series, 7.5 % of patients had a history of previous illness,
which was significantly with smoking.
Our study has some limitations. Our work can only
show association between smoking and tuberculosis
from an epidemiological point of view, and cannot show
causality.
We did not quantify daily tobacco consumption, the
number of years of smoking, type of tobacco used, or
the intensity of passive smoking, which prevents us from
evaluating a possible dose-response relationship. Only
smoking status at the time of diagnosis was recorded,
and we cannot determine if this persisted throughout
the patient’s follow-up. Thus, it was not possible to as-
sess the impact of smoking cessation on disease progres-
sion or the treatment outcome.
We could not collect systematic information on smok-
ing cessation interventions by health professionals, since
this survey depended solely on routine clinical practice
and the experience of the individual medical teams in
each of the participating centers. Some centers gave brief
anti-smoking counseling, along with basic health educa-
tion during each visit. This type of intervention has pre-
viously proven useful and feasible in other TB treatment
programs [30], but is not included in local or national
recommendations or regulations in our setting. The
introduction of drug therapy for smoking cessation in
patients with TB is still a pending task, given the limited
clinical experience available [31]; few professionals feel
prepared to advise their TB patients on smoking cessa-
tion [32], and cessation drugs are not widely accessible
due to their high price because Spain are not subsidized
by the National Health System and makes it impossible
the access groups with economic difficulties as they are
often patients with TB.
One of this study’s strong points is the large number
of cases recruited representing 12 % of total cases re-
ported in the regions that are part of the Spanish state
during the study period [33] and the quality of the infor-
mation, which allowed us to analyze trends in prevalence
during the study period and to evaluate factors associ-
ated with smoking among TB patients.
Conclusion
The prevalence of smoking among TB patients in Spain
is high. Smokers with TB have a distinct sociodemographic,
Table 1 Characteristics of 5,846 tuberculosis patients. Factors related to smoking at the time of tuberculosis diagnosis at
bivariate level (Continued)
Progressed 36 17 47,2 19 52,8 1,97(1,00;3,89) 0,049
Unknown 1079 665 61,6 414 38,4 1,10(0,92;1,31) 0,307
Treatment outcome
Unknown 520 324 62,3 196 37,7 Ref
Correct 5079 3123 61,5 1956 38,5 1,04(0,86;1,25) 0,717
Incorrect 247 99 40,1 148 59,9 2,47(1,81;3,37) <0,001
OR odds ratio
CI confidence interval
IDU injecten drug users
HVI humanimmunodeficiency virus
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Table 2 Characteristics of 5,846 tuberculosis patients. Factors related to smoking at the time of tuberculosis diagnosis at
multivariate level
Total Non-smoker Smoker Multi-variate analysis.
N 5846 N 3546 61 % N 2300 39 % OR (95 % CI) P-value
Sex
Women 2082 1556 74,7 526 25,3 Ref
Men 3626 1911 52,7 1715 47,3 2.26(1.97;2.60) <0.001
Unknown 138 79 57,2 59 42,8 2.19(1.46;3.28) <0.001
Age
Unknown 138 118 85,5 20 15,5 Ref
18–30 years 1627 1077 66,2 550 33,8 2.39(1.44;4,13) <0.001
31–50 years 2405 1212 50,4 1193 49,6 3.45(2.09;5,94 <0.001
> 50 years 1676 1139 68 537 32 2.52(1.50;4.42 <0.001
Origin
Immigrant 1941 1408 72,5 533 27,5 Ref
Native 3905 2138 54,8 1767 45,2 2,79(2,40;3,24) <0,001
Cohabitation status
Group 651 431 66,2 220 33,8 Ref
Alone 554 276 49,8 278 50,2 1,21(0,91;1,60) 0,174
Homeless 100 25 25 75 75 1,99(1,14;3,57) <0.001
Confinement 80 38 47,5 42 52,5 1,70(0,98;2,97) 0,056
With Family 4293 2683 62,5 1610 37,5 0,89(0,72;1,11) 0,317
Unknown 168 93 55,4 75 44,6 1,35(0,89;2,04) 0,147
Alcohol
No 4475 3079 68,8 1396 31,2 Ref
Yes 1371 467 34,1 904 65,9 2,85(2,46;3,31) <0,001
IDU
No 5768 3532 61,2 2236 38,8
Yes 78 14 17,9 64 82,1 2.78(1.48;5.52) <0,001
HIV
No 4547 2783 61,2 1764 38,8 0,81(0,34;2,07) 0,646
Yes 269 108 40,1 161 59,9 1,48(0,59;3,94) 0,412
Unknown 1030 655 63,5 375 36.4 Ref
Prior Treatment
No 5287 3245 61,4 2042 38,6 Ref
Yes 438 224 51,1 214 48,9 1,12(0,89;2,04) 0,314
Localization
Extra-pulmonary 611 497 81,3 114 18,7 Ref
Pulmonary 4149 2299 55,4 1850 44,6 1,61(1,16;2,24) <0,001
Disseminated 301 198 65,8 103 34,2 1,12(0,73;1,70) 0,59
Unknown 785 552 70,3 233 29,7 1,14(0,80;1,63) 0,458
Radiology
Normal 610 480 78,7 130 21,3 Ref
Abnormall cavitary 1922 889 46,3 1033 53,7 1,99(1,43;2,79) <0,001
Abnormal non cavitary 3114 2042 65,6 1072 33,4 1,24(0,91;1,70) 0,167
Unknown 200 135 67,5 65 32,5 1,21(0,77;1,89) 0,4
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clinical, radiological and microbiological profile to non-
smokers. A detailed understanding of the prevalence of
smoking in our setting, as well as sociodemographic, clin-
ical and developmental factors associated with smoking
among TB patients is the first step towards designing effect-
ive strategies for control and monitoring, with the aim of
improving the care of these patients, their clinical progres-
sion, and the treatment outcome.
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Table 2 Characteristics of 5,846 tuberculosis patients. Factors related to smoking at the time of tuberculosis diagnosis at
multivariate level (Continued)
Microbiology
Culture (−) 1055 779 73,8 276 26,2 Ref
Microscopy smear (+) 3144 1636 52 1508 48 1,39(1,14;1,71) <0,001
Microscopy smear (+), culture (−) 1647 1131 68,7 516 31,3 1,01(0,82;1,24) 0,896
OR odds ratio
CI confidence interval
IDU injecten drug users
HVI humanimmunodeficiency virus
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